Intelgenx Technologs
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral fil… Read more
Intelgenx Technologs (IGXT) - Total Liabilities
Latest total liabilities as of March 2024: $21.91 Million USD
Based on the latest financial reports, Intelgenx Technologs (IGXT) has total liabilities worth $21.91 Million USD as of March 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Intelgenx Technologs - Total Liabilities Trend (2004–2023)
This chart illustrates how Intelgenx Technologs's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Intelgenx Technologs Competitors by Total Liabilities
The table below lists competitors of Intelgenx Technologs ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Banco da Amazônia S.A
SA:BAZA3
|
Brazil | R$53.12 Billion |
|
Lider Faktoring AS
IS:LIDFA
|
Turkey | TL7.88 Billion |
|
Minera Alamos Inc
OTCQX:MAIFF
|
USA | $169.83 Million |
|
Sunndal Sparebank
OL:SUNSB
|
Norway | Nkr4.92 Billion |
|
Tropical Canning (Thailand) Public Company Limited
BK:TC
|
Thailand | ฿1.30 Billion |
|
Revoil S.A
AT:REVOIL
|
Greece | €103.35 Million |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM82.90 Million |
|
Santam
JSE:SNT
|
South Africa | ZAC65.81 Billion |
Liability Composition Analysis (2004–2023)
This chart breaks down Intelgenx Technologs's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intelgenx Technologs's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intelgenx Technologs (2004–2023)
The table below shows the annual total liabilities of Intelgenx Technologs from 2004 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $20.53 Million | +62.76% |
| 2022-12-31 | $12.61 Million | -10.13% |
| 2021-12-31 | $14.03 Million | +16.26% |
| 2020-12-31 | $12.07 Million | +12.53% |
| 2019-12-31 | $10.73 Million | +6.94% |
| 2018-12-31 | $10.03 Million | +7.65% |
| 2017-12-31 | $9.32 Million | +18.78% |
| 2016-12-31 | $7.84 Million | +134.04% |
| 2015-12-31 | $3.35 Million | +95.91% |
| 2014-12-31 | $1.71 Million | +41.52% |
| 2013-12-31 | $1.21 Million | -38.97% |
| 2012-12-31 | $1.98 Million | +197.45% |
| 2011-12-31 | $666.00K | +90.83% |
| 2010-12-31 | $349.00K | -50.46% |
| 2009-12-31 | $704.50K | -51.41% |
| 2008-12-31 | $1.45 Million | +36.87% |
| 2007-12-31 | $1.06 Million | +228.22% |
| 2006-12-31 | $322.76K | +1366.28% |
| 2005-12-31 | $22.01K | +93.27% |
| 2004-12-31 | $11.39K | -- |